Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In this video, Suneel Kamath, MD, discussed the approval of encorafenib (Braftovi, Array BioPharma) in combination with cetuximab (Erbitux, ImClone) and fluorouracil-based chemotherapy in metastatic ...
The EMA has backed new and expanded uses for multiple cancer drugs, signaling a push toward biomarker-driven, earlier-line ...
After losing his mother to colorectal cancer in 2009, Michael Sapienza turned unimaginable grief into action. Today, as CEO ...
The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove ...
Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Pierre Fabre ...
When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare ...
ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the presentation of clinical data from an ...
Daraxonrasib is the first investigational agent in a novel class of RAS (ON) multi-selective inhibitors designed to address a diverse and broad spectrum of RAS variants. In the randomized Phase 3 ...
Fee-for-service beneficiaries had higher BGP use than Medicare Advantage (25.8% vs 24.6%; AOR 1.08), indicating payer ...
Johnson & Johnson (JNJ) reported new clinical trial results showing that its experimental subcutaneous formulation of amivantamab produced durable responses in patients with advanced head and neck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results